All In Biotech

Drug Trial Radar · NCT01327638

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients

Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21,108

Actual

Start

Feb 15, 2011

Primary completion

Sep 24, 2018

Study completion Dec 6, 2018

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Apr 1, 2011

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.

Conditions

  • Spondylarthropathies; Spondylitis, Ankylosing

Interventions

  • etoricoxibDrug

    Patients with SpA/AS who took etoricoxib

  • Other COX-2 inhibitorDrug

    Patients with SpA/AS who took other COX-2 inhibitors

  • nsNSAIDsDrug

    Patients with SpA/AS who took nsNSAIDs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with Characteristics of inflammatory SPA/ASTime frame: Over a 12 year period (2001-2013)
  2. Number of patients who used etoricoxibTime frame: Up to 7 1/2 years (Q3 2005 - 2013)
  3. Number of patients who used other COX-2 inhibitorsTime frame: Up to 7 1/2 years (Q3 2005 - 2013)
  4. Number of patients who used nsNSAIDsTime frame: Up to 7 1/2 years (Q3 2005 - 2013)
  5. Number of clinical outcomes of special interestTime frame: Up to 7 1/2 years (Q3 2005 - 2013)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.